Core Viewpoint - Analysts project that Teleflex will report quarterly earnings of $3.33 per share, reflecting a decline of 2.4% year over year, with revenues expected to reach $763.39 million, an increase of 2.7% from the same quarter last year [10] Revenue Estimates - 'Net Revenues- Anesthesia' is estimated to be $104.01 million, indicating a change of +3.2% from the year-ago quarter [2] - 'Geographic Revenues- EMEA' is expected to be $157.16 million, showing a change of +6.3% from the year-ago quarter [3] - 'Net Revenues- Interventional Urology' is projected at $83.48 million, reflecting a change of +7.3% from the prior-year quarter [5] - 'Net Revenues- Surgical' is forecasted to reach $111.50 million, indicating a change of +5.2% from the prior-year quarter [6] - 'Revenues- OEM (Original Equipment Manufacturer and Development Services)' is estimated at $88.27 million, suggesting a change of +5% year over year [8] - 'Geographic Revenues- Americas' is likely to reach $432.19 million, indicating a change of +1.8% year over year [9] - 'Net Revenues- Interventional' is estimated at $137.89 million, reflecting a change of +10.5% year over year [11] - 'Net Revenues- Other' is projected to be $55.13 million, indicating a change of -27.5% year over year [12] - 'Net Revenues- Vascular Access' is expected to reach $181.31 million, showing a year-over-year change of +4.3% [14] - 'Geographic Revenues- Asia' is forecasted to be $87.90 million, indicating a change of +1.4% from the year-ago quarter [15] Earnings Estimate Revisions - Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter, indicating that analysts have not changed their initial forecasts during this period [4] Stock Performance - Teleflex shares have experienced a change of +5.4% in the past month, compared to a -0.4% move of the Zacks S&P 500 composite, with a Zacks Rank 3 (Hold) suggesting that TFX is expected to mirror overall market performance in the near future [7]

The Ringer™ PBC is a rapid-exchange 0.014" compatible catheter with a unique helical balloon at its working end. When inflated, this balloon approximates a hollow cylinder with a large central perfusion lumen. These characteristics allow for continuous coronary blood flow during prolonged inflations.2 The Ringer™ PBC is indicated for balloon dilatation of coronary artery or coronary bypass graft stenoses where the physician desires distal blood perfusion during balloon inflation for the purpose of improving ...

WAYNE, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon.1 "The Ringer PTCA Clinical Study demonstrated that inflation of the Ringer™ PBC for 60 seconds or more was well tolerated in the majority of patients who ...

QuikClot™ Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3 enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers ...

Premier's SURPASS® program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier's most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing. "QuikClot™ Hemostatic Dressings and the ...

Company Overview - Teleflex (TFX) is anticipated to report a year-over-year decline in earnings despite higher revenues for the quarter ended June 2024, with a consensus EPS estimate of $3.33, reflecting a -2.4% change from the previous year [1][3][4]. Earnings Expectations - Revenues are projected to be $763.39 million, which is a 2.7% increase compared to the same quarter last year [5]. - The consensus EPS estimate has been revised down by 0.02% over the last 30 days, indicating a reassessment by analysts [5]. Earnings Surprise Prediction - The Most Accurate Estimate for Teleflex is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.66%, suggesting a bearish outlook from analysts [11]. - The stock currently holds a Zacks Rank of 3 (Hold), complicating predictions of an earnings beat [12][13]. Historical Performance - In the last reported quarter, Teleflex exceeded the expected EPS of $3.07 by delivering $3.21, resulting in a surprise of +4.56% [14]. - Over the past four quarters, the company has successfully beaten consensus EPS estimates four times [15]. Industry Comparison - Glaukos (GKOS), another player in the medical instruments industry, is expected to report an EPS of $0.52 for the same quarter, indicating a +5.5% year-over-year change, with revenues expected to reach $88.41 million, up 10% from the previous year [19]. - Glaukos has also seen a downward revision in its consensus EPS estimate by 0.9% over the last 30 days, leading to an Earnings ESP of -0.96% and a Zacks Rank of 3 [20].

Core Viewpoint - Teleflex Incorporated has established the Teleflex Center for Antimicrobial Protection (TCAP) to enhance its Vascular Access business unit, focusing on reducing infections related to vascular access procedures [1][6]. Group 1: Company Overview - Teleflex is a global provider of medical technologies, offering a diverse portfolio that includes trusted brands such as Arrow™, Barrigel™, and QuikClot™ [3][9]. - The company aims to improve health and quality of life through innovative solutions in various therapy areas, including anesthesia, emergency medicine, and vascular access [9]. Group 2: TCAP Initiatives - TCAP is dedicated to combating infections caused by multidrug-resistant organisms, often referred to as "superbugs," which can complicate patient care and extend hospital stays [6]. - The center focuses on education and partnerships with healthcare professionals to serve as a resource for infection prevention [6][7]. - TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically targeting central line-associated bloodstream infections (CLABSI) [2][6]. Group 3: Product Offerings - Teleflex's Arrow™ brand features a comprehensive portfolio of antimicrobial Chlorhexidine catheters that provide broad-spectrum protection against various pathogens [8]. - The company also offers Arrow™ Maximal Barrier Kitting options to enhance patient protection and improve procedural efficiency for clinicians [8].

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginn ...

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginn ...

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Revisions for Teleflex Analysts ...